Endocrine Abstracts

Peptide Receptor Radiotherapy (PRRT) is playing an increasingly important role in the management of gastroenteropancreatic (GEP) NETs. In this session we will consider the principles behind this treatment modality, and review the existing data demonstrating the benefit of PRRT to patients with GEP NETs. We will discuss the current position of PRRT in international guidelines regarding the management of GEP NETS. We will further consider on-going research to derive greater benefits from this treatment, including opportunities to personalise therapy via individual patient dosimetry, the use of novel ligands and novel radionuclides, and the possiblity of combination therapies, for example with radiosensitisers and with immunotherapy.